BCC
KRYS icon

Bridge City Capital’s Krystal Biotech KRYS Stock Holding History

Bridge City Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.11M Sell
12,045
-90
-0.7% -$23.9K 0.86% 44
2025
Q4 		$2.99M Sell
12,135
-2,019
-14% -$425K 0.88% 49
2025
Q3 		$2.5M Buy
+14,154
New +$2.12M 0.67% 69

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridge City Capital's KRYS Position: Q1 2026 in Review

Bridge City Capital reduced its Krystal Biotech (KRYS) stake by 0.74% in Q1 2026, selling an estimated $23.9K and leaving 12,045 shares worth $3.11M. The position accounts for 0.86% of the portfolio, ranked #44.

Bridge City Capital first reported a position in KRYS in Q3 2025 and has held it in 3 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Bridge City Capital held 12,045 shares of Krystal Biotech worth $3.11M as of Q1 2026.
  • Bridge City Capital sold 90 Krystal Biotech shares in Q1 2026, an estimated $23.9K.
  • Krystal Biotech made up 0.86% of Bridge City Capital's portfolio in Q1 2026, its #44 holding.
  • Bridge City Capital first reported a position in Krystal Biotech in Q3 2025 and has held it in 3 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Bridge City Capital's 13F filing for Q1 2026, filed 13 May 2026.